- Home
- VRNA vs JAZZ Comparison
VRNA vs JAZZ Comparison
Compare VRNA & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRNA
- JAZZ
- Stock Information
- Founded
- VRNA 2005
- JAZZ 2003
- Country
- VRNA United Kingdom
- JAZZ Ireland
- Employees
- VRNA N/A
- JAZZ N/A
- Industry
- VRNA Biotechnology: Pharmaceutical Preparations
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- VRNA Health Care
- JAZZ Health Care
- Exchange
- VRNA Nasdaq
- JAZZ Nasdaq
- Market Cap
- VRNA 8.3B
- JAZZ 6.7B
- IPO Year
- VRNA 2017
- JAZZ 2007
- Fundamental
- Price
- VRNA $94.58
- JAZZ $106.12
- Analyst Decision
- VRNA Strong Buy
- JAZZ Strong Buy
- Analyst Count
- VRNA 8
- JAZZ 12
- Target Price
- VRNA $105.38
- JAZZ $183.08
- AVG Volume (30 Days)
- VRNA 1.2M
- JAZZ 678.5K
- Earning Date
- VRNA 08-07-2025
- JAZZ 07-30-2025
- Dividend Yield
- VRNA N/A
- JAZZ N/A
- EPS Growth
- VRNA N/A
- JAZZ 49.21
- EPS
- VRNA N/A
- JAZZ 7.51
- Revenue
- VRNA $118,535,000.00
- JAZZ $4,064,808,000.00
- Revenue This Year
- VRNA $891.79
- JAZZ $6.05
- Revenue Next Year
- VRNA $78.94
- JAZZ $4.68
- P/E Ratio
- VRNA N/A
- JAZZ $14.09
- Revenue Growth
- VRNA N/A
- JAZZ 5.76
- 52 Week Low
- VRNA $14.15
- JAZZ $95.49
- 52 Week High
- VRNA $99.01
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- VRNA 68.57
- JAZZ 43.01
- Support Level
- VRNA $92.88
- JAZZ $105.57
- Resistance Level
- VRNA $99.01
- JAZZ $109.21
- Average True Range (ATR)
- VRNA 3.09
- JAZZ 2.54
- MACD
- VRNA -0.40
- JAZZ -0.25
- Stochastic Oscillator
- VRNA 69.04
- JAZZ 10.60
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.